Imran Petkar1,2, Dualta McQuaid3, Alex Dunlop3, Justine Tyler4, Emma Hall5, Chris Nutting1,2. 1. Head and Neck Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom. 2. Division of Radiotherapy and Imaging, Institute of Cancer Research, London, United Kingdom. 3. Joint Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom. 4. Department of Physics, Royal Marsden NHS Foundation Trust, London, United Kingdom. 5. Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom.
Abstract
BACKGROUND AND PURPOSE: To evaluate the inter-observer variation (IOV) in pharyngeal constrictor muscle (PCM) contouring, and resultant impact on dosimetry and estimated toxicity, as part of the pre-trial radiotherapy trial quality assurance (RTQA) within DARS, a multicenter phase III randomized controlled trial investigating the functional benefits of dysphagia-optimized intensity-modulated radiotherapy (Do-IMRT) in pharyngeal cancers. METHODS AND MATERIALS: Outlining accuracy of 15 clinicians' superior and middle PCM (SMPCM) and inferior PCM (IPCM) were retrospectively assessed against gold standards (GS) using volume, location, and conformity indices (CIs) on a pre-trial benchmark case of oropharyngeal cancer. The influence of delineation variability on dose delivered to the constrictor muscles with Do-IMRT and resultant normal tissue complication probability (NTCP) for physician-scored radiation-associated dysphagia at 6 months was evaluated. RESULTS: For GS, SMPCM, and IPCM volumes were 13.51 and 1.67 cm3; corresponding clinician mean volumes were 12.18 cm3 (SD 3.0) and 2.40 cm3 (SD 0.9) respectively. High IOV in SMPCM and IPCM delineation was observed by the low DICE similarity coefficient value, along with high geographical miss index and discordance index values. Delineation variability did not significantly affect the mean dose delivered to the constrictors, relative to the GS plan. Mean clinician NTCP was 24.6% (SD 0.6), compared to the GS-NTCP of 24.7%. CONCLUSIONS: Results from this benchmark case demonstrate that inaccurate PCM delineation existed, even with protocol guidelines. This did not impact on delivered dose to this structure with Do-IMRT, or on estimated swallowing toxicity, in this single benchmark case.
BACKGROUND AND PURPOSE: To evaluate the inter-observer variation (IOV) in pharyngeal constrictor muscle (PCM) contouring, and resultant impact on dosimetry and estimated toxicity, as part of the pre-trial radiotherapy trial quality assurance (RTQA) within DARS, a multicenter phase III randomized controlled trial investigating the functional benefits of dysphagia-optimized intensity-modulated radiotherapy (Do-IMRT) in pharyngeal cancers. METHODS AND MATERIALS: Outlining accuracy of 15 clinicians' superior and middle PCM (SMPCM) and inferior PCM (IPCM) were retrospectively assessed against gold standards (GS) using volume, location, and conformity indices (CIs) on a pre-trial benchmark case of oropharyngeal cancer. The influence of delineation variability on dose delivered to the constrictor muscles with Do-IMRT and resultant normal tissue complication probability (NTCP) for physician-scored radiation-associated dysphagia at 6 months was evaluated. RESULTS: For GS, SMPCM, and IPCM volumes were 13.51 and 1.67 cm3; corresponding clinician mean volumes were 12.18 cm3 (SD 3.0) and 2.40 cm3 (SD 0.9) respectively. High IOV in SMPCM and IPCM delineation was observed by the low DICE similarity coefficient value, along with high geographical miss index and discordance index values. Delineation variability did not significantly affect the mean dose delivered to the constrictors, relative to the GS plan. Mean clinician NTCP was 24.6% (SD 0.6), compared to the GS-NTCP of 24.7%. CONCLUSIONS: Results from this benchmark case demonstrate that inaccurate PCM delineation existed, even with protocol guidelines. This did not impact on delivered dose to this structure with Do-IMRT, or on estimated swallowing toxicity, in this single benchmark case.
Authors: Christos Melidis; Walther R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Kenneth Ulin; Satoshi Ishikura; David Followill; James Galvin; Annette Haworth; Deidre Besuijen; Catharine H Clark; Clark H Clark; Elizabeth Miles; Edwin Aird; Damien C Weber; Coen W Hurkmans; Dirk Verellen Journal: Int J Radiat Oncol Biol Phys Date: 2014-12-01 Impact factor: 7.038
Authors: Hans Paul van der Laan; Miranda E M C Christianen; Hendrik P Bijl; Cornelis Schilstra; Johannes A Langendijk Journal: Radiother Oncol Date: 2011-11-21 Impact factor: 6.280
Authors: Miranda E M C Christianen; Arjen van der Schaaf; Hans Paul van der Laan; Irma M Verdonck-de Leeuw; Patricia Doornaert; Olga Chouvalova; Roel J H M Steenbakkers; Charles René Leemans; Sjoukje F Oosting; Bernard F A M van der Laan; Jan L N Roodenburg; Ben J Slotman; Hendrik P Bijl; Johannes A Langendijk Journal: Radiother Oncol Date: 2015-12-14 Impact factor: 6.280
Authors: Imran Petkar; Keith Rooney; Justin W G Roe; Joanne M Patterson; David Bernstein; Justine M Tyler; Marie A Emson; James P Morden; Kathrin Mertens; Elizabeth Miles; Matthew Beasley; Tom Roques; Shreerang A Bhide; Kate L Newbold; Kevin J Harrington; Emma Hall; Christopher M Nutting Journal: BMC Cancer Date: 2016-10-06 Impact factor: 4.430
Authors: Waheeda Owadally; Chris Hurt; Hayley Timmins; Emma Parsons; Sarah Townsend; Joanne Patterson; Katherine Hutcheson; Ned Powell; Matthew Beasley; Nachi Palaniappan; Max Robinson; Terence M Jones; Mererid Evans Journal: BMC Cancer Date: 2015-08-27 Impact factor: 4.430
Authors: Aditi Iyer; Maria Thor; Ifeanyirochukwu Onochie; Jennifer Hesse; Kaveh Zakeri; Eve LoCastro; Jue Jiang; Harini Veeraraghavan; Sharif Elguindi; Nancy Y Lee; Joseph O Deasy; Aditya P Apte Journal: Phys Med Biol Date: 2022-01-17 Impact factor: 3.609